Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Transcenta Holding Limited ( (HK:6628) ) has shared an announcement.
Transcenta Holding Limited announced promising preclinical results for its novel FGFR2b-targeted ADC, TST105, at the AACR Annual Meeting 2025. The ADC demonstrated significantly enhanced anti-tumor activity compared to existing MMAE-based ADCs in gastric and colorectal tumor models. With a novel topoisomerase I inhibitor payload and site-specific conjugation, TST105 showed superior tumor growth inhibition and overall response rates. This advancement positions Transcenta as a potential leader in developing transformative cancer therapies, with plans to advance TST105 into clinical development.
More about Transcenta Holding Limited
Transcenta Holding Limited is a biotechnology company focused on developing innovative therapies for cancer treatment. The company specializes in antibody-drug conjugates (ADCs) targeting specific cancer markers, with a strong emphasis on addressing cancers with high FGFR2b overexpression.
YTD Price Performance: 100.0%
Average Trading Volume: 1,195,787
Technical Sentiment Signal: Buy
Current Market Cap: HK$537.1M
See more data about 6628 stock on TipRanks’ Stock Analysis page.